Target Group subsidiary receives CDN$2.04M payout from Thrive, JV continues

Target Group Inc.

CanaryRx (Target Group subsidiary) received CDN$2,043,082.74 from Thrive to fully repay JV indebtedness.
Thrive paid the amount on May 6, 2022, satisfying all Outstanding JV and Product Obligations.
The Joint Venture Operations Agreement between CanaryRx, Thrive, and JVCo remains in full force.
The payout covers start-up hard costs ($921,581.48) and excess costs ($1,121,501.26).
The agreement facilitates Thrive's parent Terrafarma's planned amalgamation with Aurora Cannabis Inc.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.